Shattuck Labs Inc STTK:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 12:08 PM EDT
10.71quote price arrow down-0.04 (-0.37%)
Volume
64,268
52 week range
1.33 - 11.62
Loading...
  • Open10.62
  • Day High10.89
  • Day Low10.39
  • Prev Close10.75
  • 52 Week High11.62
  • 52 Week High Date05/03/24
  • 52 Week Low1.33
  • 52 Week Low Date10/06/23

Key Stats

  • Market Cap509.27M
  • Shares Out47.55M
  • 10 Day Average Volume0.29M
  • Dividend-
  • Dividend Yield-
  • Beta1.99
  • YTD % Change50.35

KEY STATS

  • Open10.62
  • Day High10.89
  • Day Low10.39
  • Prev Close10.75
  • 52 Week High11.62
  • 52 Week High Date05/03/24
  • 52 Week Low1.33
  • 52 Week Low Date10/06/23
  • Market Cap509.27M
  • Shares Out47.55M
  • 10 Day Average Volume0.29M
  • Dividend-
  • Dividend Yield-
  • Beta1.99
  • YTD % Change50.35

RATIOS/PROFITABILITY

  • EPS (TTM)-1.93
  • P/E (TTM)-5.55
  • Fwd P/E (NTM)-6.42
  • EBITDA (TTM)-86.038M
  • ROE (TTM)-59.40%
  • Revenue (TTM)2.715M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-3,133.63%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/08/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Shattuck Labs Inc

 

Profile

MORE
Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B...
George Golumbeski Ph.D.
Independent Chairman of the Board
Taylor Schreiber M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Andrew Neill
Chief Financial Officer
Stephen Stout Ph.D.
Deputy General Counsel, Vice President - Intellectual Property
Address
500 W. 5Th Street, Suite 100
Austin, TX
78701
United States

Top Peers

SYMBOLLASTCHG%CHG
KALV
Kalvista Pharmaceuticals Inc
12.09-0.10-0.82%
ALT
Altimmune Inc
7.37+0.10+1.31%
NKTX
Nkarta Inc
6.42-0.38-5.59%
ALLO
Allogene Therapeutics Inc
2.78-0.13-4.47%
ATXS
Astria Therapeutics Inc
9.73-0.25-2.45%